BridgeBio's encaleret shows broad symptom gains in Phase 3 CALIBRATE; next trial underway

What's the deal? BridgeBio presented new Phase 3 data for its experimental oral medicine encaleret in autosomal dominant hypocalcaemia type 1 (ADH1) at the American Society for Bone and Mineral Research (ASBMR) 2026 annual meeting in Boston on 11 October 2026. ADH1 is a rare inherited condition in which the body cannot regulate blood calcium properly, causing symptoms such as muscle cramps, spasms, tingling, fatigue and “brain fog”. Encaleret works by acting on the calcium-sensing receptor to restore the body's own calcium-control mechanism.

The data: 100% of patients who received encaleret reported improvement in at least one ADH1 symptom, versus 46% on standard care (calcium supplements and/or active vitamin D). The medicine restored secretion of parathyroid hormone (the hormone that regulates calcium) to normal levels in 91% of patients, versus 0% on standard care, and increased markers of bone formation and breakdown — evidence that it is addressing the underlying biology of the disease rather than just correcting blood calcium. Improvement rates on encaleret versus standard care included fatigue (61.3% vs 27.3%), muscle cramps (58.1% vs 36.4%), muscle spasms (58.1% vs 18.2%), tingling (51.6% vs 9.1%) and brain fog (48.4% vs 9.1%).

Why it matters: Encaleret was developed by Calcilytix Therapeutics, a BridgeBio subsidiaryDealroom has a profile for this one. Try Dealroom →. The US Food and Drug Administration has accepted BridgeBio's application for encaleret in ADH1 with Priority Review and a target decision date of 8 May 2027, and BridgeBio has also submitted an application to the European Medicines Agency. The company has additionally dosed the first participant in RECLAIM-HP, a registration trial evaluating encaleret in chronic hypoparathyroidism, a related and more common calcium-regulation disorder, which could substantially widen the medicine's market beyond ADH1.

Read more: GlobeNewswire, 11 October 2026